70/100

Moderate evidence

Cite
More
EmailLinkedInX

Across 30 studies, AI outlines cervical cancer on MRI with uneven accuracy and weak evidence

Study title: Deep Learning and Machine Learning Algorithms for Cervical Cancer Segmentation on MRI: A Systematic Review

Evidence type
Systematic review or meta-analysis
Sample
n = 30
Sources
1 sourcePeer-reviewed
Published
1 min read

Study title: Deep Learning and Machine Learning Algorithms for Cervical Cancer Segmentation on MRI: A Systematic Review

This PRISMA-guided systematic review of 30 studies up to December 2025 evaluated machine learning and deep learning algorithms for automated cervical cancer segmentation on MRI, a task central to staging and treatment planning that is currently manual and variable.

Read the study abstract

Introduction Cervical cancer management relies heavily on magnetic resonance imaging (MRI) for staging and treatment planning; however, manual segmentation is time-consuming and prone to variability. This systematic review aimed to evaluate the performance and clinical potential of machine learning (ML) and deep learning (DL) algorithms for automated cervical cancer segmentation on MRI. Methods A systematic review guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (PROSPERO…

56Gain side

How the two sides scoreProblem scores higher

66Problem side

The gain

In 30 studies, AI models outlined cervical tumours and nearby structures on MRI with Dice overlap scores of 0.60 to 0.93, though efficiency gains were only potential.

The problem

A systematic review of 30 studies found some concerns for bias and low certainty of evidence, with limited external validation and accuracy that varied by target structure and imaging protocol, so clinical readiness is unproven.

A fixed formula sets both scores from the evidence and its sources. Reader votes don’t move them.

What the scores mean

G is the gain side, out of 100. It goes up when the gain is specific, when it measurably helped people and when the sources behind it are strong.

P is the problem side, out of 100. It goes up when the problem is specific, when it measurably hurt people and when the sources behind it are strong.

In brief

While models showed Dice scores between 0.60 and 0.93 and potential efficiency gains, the review found some concerns for bias and low certainty of evidence, leaving uncertainty about generalizability across protocols and centers and the timeline for clinical adoption.

Main points

  1. Systematic review included 30 studies identified via PRISMA search of six databases until December 2025, registered as PROSPERO: CRD420251247441.
  2. Primary focus was MRI-based segmentation of tumours, high-risk clinical target volumes, and organs at risk, with CT and PET multimodal studies as complementary evidence.
  3. Risk of bias assessed with QUADAS-2 showed some concerns related to patient selection and reference standards.

The full story

The review searched PubMed/MEDLINE, Embase, Scopus, Web of Science, IEEE Xplore, and Google Scholar until December 2025, with two reviewers screening and extracting data. Thirty studies were included, evaluating U-Net variants, convolutional neural networks, and transformer-based architectures.

Performance varied according to target structure, tumour characteristics, and imaging protocols, with Dice coefficients from 0.60 to 0.93. Authors concluded promising potential but called for multicenter studies with standardized protocols and external validation before routine use.

What this doesn’t fix

Evidence certainty is limited by heterogeneity across imaging protocols and targets, methodological limitations, and lack of external validation, preventing routine clinical use.

Sources

1 on file
  1. Peer-reviewed2026-09-27

Talk it over

Three questions to start on, two more if you have time
The 30 studies reported Dice scores from 0.60 to 0.93, but the review found low certainty of evidence. How would you weigh that range of accuracy against the gaps in the evidence?

Start with a question

Across 30 studies, AI outlines cervical cancer on MRI with uneven accuracy and weak evidencehttps://truvace.com/item/deep-learning-and-machine-learning-algorithms-for-cervical-cancer-segmentation-o

  1. The 30 studies reported Dice scores from 0.60 to 0.93, but the review found low certainty of evidence. How would you weigh that range of accuracy against the gaps in the evidence?

    Answer in the thread
  2. The review found some concerns about patient selection and reference standards in the 30 studies. How could those concerns make the Dice scores look better or worse than they would be in practice?

    Answer in the thread
  3. The authors called for multicenter studies with standardized protocols and external validation before routine use. Who should decide when that evidence is enough, and what would they need to see?

    Answer in the thread
If you have more time
  • Performance varied by target structure and imaging protocol. Which would you want to see reported separately for tumours, high-risk clinical target volumes and organs at risk, and why?

    Answer in the thread
  • Look up how staging and treatment planning for cervical cancer is done by hand now. What would a fair head-to-head test between a clinician's outline and an AI outline look like?

    Answer in the thread

What readers say